Clarity Pharmaceuticals reports seven complete cancer responses

• Clarity Pharmaceuticals reported seven total complete responses in its SECuRE cancer trial.
• Following the announcement, shares in the company rose 6.7% to $2.69.
• The business aims to continue expanding cohort recruitment to progress its radiopharmaceutical therapy platform.

Clarity Pharmaceuticals (ASX:CU6) reported two new complete responses in its SECuRE prostate cancer trial.

The latest update brings the total complete responses across the therapy programme to seven patients.

Trial data showed 74% of evaluable participants achieved significant reductions in prostate-specific antigen levels.

Radiographic assessments confirmed disease control in 81% of evaluable participants, with mostly mild side effects.

Following the announcement, the Clarity Pharmaceuticals share price was up 6.7% at $2.69.

The business develops targeted radiopharmaceutical therapies using its proprietary SAR platform to treat serious conditions.

The company stated that trial recruitment remains ongoing to support further clinical development.